125 related articles for article (PubMed ID: 38903594)
1. The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis.
Qin Z; He M; Shen H; Liu S; Xu S; Chen L
Front Public Health; 2024; 12():1381786. PubMed ID: 38903594
[TBL] [Abstract][Full Text] [Related]
2. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
[TBL] [Abstract][Full Text] [Related]
3. Impact of China's zero mark-up drug policy on drug cost of NCDs' outpatients: an interrupted time series analysis.
Du J; Xie J; Qian Y; Wu M; Huang W; Yin J; Peng X; Deng D
BMC Health Serv Res; 2021 Apr; 21(1):404. PubMed ID: 33926444
[TBL] [Abstract][Full Text] [Related]
4. Impact of Critical Illness Insurance on the Burden of High-Cost Rural Residents in Central China: An Interrupted Time Series Study.
Li L; Jiang J; Xiang L; Wang X; Zeng L; Zhong Z
Int J Environ Res Public Health; 2019 Sep; 16(19):. PubMed ID: 31547215
[TBL] [Abstract][Full Text] [Related]
5. Impacts of unifying urban and rural residents' medical insurance on the hospitalisation expenses of rural patients in eastern China: an interrupted time series analysis.
Qin Z; Liu S; Zhou M; Chen L; Huang W; Shen L
BMJ Open; 2023 May; 13(5):e067198. PubMed ID: 37230522
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effectiveness of comprehensive drug price reform: a case study from Shihezi city in Western China.
Lin T; Wu Z; Liu M; Wu X; Zhang X
Int J Equity Health; 2020 Aug; 19(1):133. PubMed ID: 32762691
[TBL] [Abstract][Full Text] [Related]
7. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.
Wang J; Li P; Wen J
BMC Health Serv Res; 2020 Jun; 20(1):519. PubMed ID: 32513170
[TBL] [Abstract][Full Text] [Related]
8. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.
Cai L; Tao T; Li H; Zhang Z; Zhang L; Li X
J Glob Health; 2022 Dec; 12():11016. PubMed ID: 36527382
[TBL] [Abstract][Full Text] [Related]
9. The impact of DRG on resource consumption of inpatient with ischemic stroke.
Wei A; Ren J; Feng W
Front Public Health; 2023; 11():1213931. PubMed ID: 38026323
[TBL] [Abstract][Full Text] [Related]
10. Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis.
Li C; Zhu J; Shan L; Zhou Y; Liu G; Zhu H; Wu Q; Cui Y; Kang Z
BMC Health Serv Res; 2024 Jan; 24(1):90. PubMed ID: 38233857
[TBL] [Abstract][Full Text] [Related]
11. The Effect of the Full Coverage of Essential Medicines Policy on Utilization and Accessibility of Primary Healthcare Service for Rural Seniors: A Time Series Study in Qidong, China.
Wang Y; Zhu Y; Shi H; Sun X; Chen N; Li X
Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31698773
[No Abstract] [Full Text] [Related]
12. The impact of an innovative payment method on medical expenditure, efficiency, and quality for inpatients with different types of medical insurance: evidence from a pilot city, China.
Lin K; Li Y; Yao Y; Xiong Y; Xiang L
Int J Equity Health; 2024 Jun; 23(1):115. PubMed ID: 38840102
[TBL] [Abstract][Full Text] [Related]
13. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
Lan T; Guan L; Pang X; Li X; Yu Q
J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
[TBL] [Abstract][Full Text] [Related]
14. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.
Yang Y; Zhang Y; Wagner AK; Li H; Shi L; Guan X
J Glob Health; 2023 Aug; 13():04083. PubMed ID: 37566690
[TBL] [Abstract][Full Text] [Related]
15. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
[TBL] [Abstract][Full Text] [Related]
16. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis.
Zhang L; Wang X; Yao H; Ding B; Gao X; Li X
Int J Equity Health; 2024 Jun; 23(1):116. PubMed ID: 38840134
[TBL] [Abstract][Full Text] [Related]
17. Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.
Zhu D; Shi X; Nicholas S; Bai Q; He P
BMJ Open; 2019 Aug; 9(8):e029646. PubMed ID: 31401602
[TBL] [Abstract][Full Text] [Related]
18. Interrupted time series analysis for the impact of integrated medical insurance on direct hospitalization expense of catastrophic illness.
Niu L; Song Q; Liu Y; Wang X
Sci Rep; 2022 Jul; 12(1):12316. PubMed ID: 35854019
[TBL] [Abstract][Full Text] [Related]
19. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
Rong X; Yin J; Duan S; Sun Q; Babar ZU
BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
[TBL] [Abstract][Full Text] [Related]
20. The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis.
Ding Y; Zheng C; Wei X; Zhang Q; Sun Q
BMC Public Health; 2022 Dec; 22(1):2363. PubMed ID: 36527037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
